Literature DB >> 11342573

Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice.

Y Imanishi1, Y Hosokawa, K Yoshimoto, E Schipani, S Mallya, A Papanikolaou, O Kifor, T Tokura, M Sablosky, F Ledgard, G Gronowicz, T C Wang, E V Schmidt, C Hall, E M Brown, R Bronson, A Arnold.   

Abstract

The relationship between abnormal cell proliferation and aberrant control of hormonal secretion is a fundamental and poorly understood issue in endocrine cell neoplasia. Transgenic mice with parathyroid-targeted overexpression of the cyclin D1 oncogene, modeling a gene rearrangement found in human tumors, were created to determine whether a primary defect in this cell-cycle regulator can cause an abnormal relationship between serum calcium and parathyroid hormone response, as is typical of human primary hyperparathyroidism. We also sought to develop an animal model of hyperparathyroidism and to examine directly cyclin D1's role in parathyroid tumorigenesis. Parathyroid hormone gene regulatory region--cyclin D1 (PTH--cyclin D1) mice not only developed abnormal parathyroid cell proliferation, but also developed chronic biochemical hyperparathyroidism with characteristic abnormalities in bone and, notably, a shift in the relationship between serum calcium and PTH. Thus, this animal model of human primary hyperparathyroidism provides direct experimental evidence that overexpression of the cyclin D1 oncogene can drive excessive parathyroid cell proliferation and that this proliferative defect need not occur solely as a downstream consequence of a defect in parathyroid hormone secretory control by serum calcium, as had been hypothesized. Instead, primary deregulation of cell-growth pathways can cause both the hypercellularity and abnormal control of hormonal secretion that are almost inevitably linked together in this common disorder.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11342573      PMCID: PMC209274          DOI: 10.1172/JCI10523

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  38 in total

1.  Nonlinear mixed effects models for repeated measures data.

Authors:  M L Lindstrom; D M Bates
Journal:  Biometrics       Date:  1990-09       Impact factor: 2.571

Review 2.  Immortalization of neuroendocrine cells by targeted oncogenesis.

Authors:  P L Mellon; J J Windle; R I Weiner
Journal:  Recent Prog Horm Res       Date:  1991

3.  Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes.

Authors:  D Hanahan
Journal:  Nature       Date:  1985 May 9-15       Impact factor: 49.962

4.  PRAD1/cyclin D1 proto-oncogene: genomic organization, 5' DNA sequence, and sequence of a tumor-specific rearrangement breakpoint.

Authors:  T Motokura; A Arnold
Journal:  Genes Chromosomes Cancer       Date:  1993-06       Impact factor: 5.006

5.  SV40 T antigen transforms calcitonin cells of the thyroid but not CGRP-containing neurons in transgenic mice.

Authors:  M Baetscher; E Schmidt; A Shimizu; P Leder; M C Fishman
Journal:  Oncogene       Date:  1991-07       Impact factor: 9.867

6.  Nucleotide sequence of the human parathyroid hormone gene.

Authors:  T J Vasicek; B E McDevitt; M W Freeman; B J Fennick; G N Hendy; J T Potts; A Rich; H M Kronenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

7.  Calcium infusion suggests a "set-point" abnormality of parathyroid gland function in familial benign hypercalcemia and more complex disturbances in primary hyperparathyroidism.

Authors:  S Khosla; P R Ebeling; A F Firek; M M Burritt; P C Kao; H Heath
Journal:  J Clin Endocrinol Metab       Date:  1993-03       Impact factor: 5.958

8.  Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism.

Authors:  M R Pollak; E M Brown; Y H Chou; S C Hebert; S J Marx; B Steinmann; T Levi; C E Seidman; J G Seidman
Journal:  Cell       Date:  1993-12-31       Impact factor: 41.582

9.  A novel cyclin encoded by a bcl1-linked candidate oncogene.

Authors:  T Motokura; T Bloom; H G Kim; H Jüppner; J V Ruderman; H M Kronenberg; A Arnold
Journal:  Nature       Date:  1991-04-11       Impact factor: 49.962

10.  Monoclonal antibody against PRAD1/cyclin D1 stains nuclei of tumor cells with translocation or amplification at BCL-1 locus.

Authors:  S Banno; K Yoshikawa; S Nakamura; K Yamamoto; T Seito; M Nitta; T Takahashi; R Ueda; M Seto
Journal:  Jpn J Cancer Res       Date:  1994-09
View more
  53 in total

1.  Cycling with the parathyroid.

Authors:  J Silver
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

Review 2.  The hunting of the snark: the elusive calcium receptor(s).

Authors:  Lawrence G Raisz
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

Review 3.  Comparative pathogenesis of epsilonretroviruses.

Authors:  Donald Holzschu; Lorie A Lapierre; Michael D Lairmore
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

4.  Tissue-specific regulatory regions of the PTH gene localized by novel chromosome 11 rearrangement breakpoints in a parathyroid adenoma.

Authors:  Sanjay M Mallya; H Irene Wu; Elizabeth A Saria; Kristin R Corrado; Andrew Arnold
Journal:  J Bone Miner Res       Date:  2010-07-16       Impact factor: 6.741

5.  Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice.

Authors:  Manshan Xu; Shilpa Choudhary; Olga Voznesensky; Qi Gao; Douglas Adams; Vilmaris Diaz-Doran; Qian Wu; David Goltzman; Lawrence G Raisz; Carol C Pilbeam
Journal:  Bone       Date:  2010-05-13       Impact factor: 4.398

6.  Menin represses tumorigenesis via repressing cell proliferation.

Authors:  Ting Wu; Xianxin Hua
Journal:  Am J Cancer Res       Date:  2011-05-16       Impact factor: 6.166

7.  Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels.

Authors:  Takehisa Kawata; Yasuo Imanishi; Keisuke Kobayashi; Naoyoshi Onoda; Senji Okuno; Yoshiaki Takemoto; Takeshi Komo; Hideki Tahara; Michihito Wada; Nobuo Nagano; Eiji Ishimura; Takami Miki; Tetsuro Ishikawa; Masaaki Inaba; Yoshiki Nishizawa
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

Review 8.  The calcium-sensing receptor in bone--mechanistic and therapeutic insights.

Authors:  David Goltzman; Geoffrey N Hendy
Journal:  Nat Rev Endocrinol       Date:  2015-03-10       Impact factor: 43.330

9.  Parathyroid-specific interaction of the calcium-sensing receptor and G alpha q.

Authors:  Min Pi; Ling Chen; MinZhao Huang; Qiang Luo; L Darryl Quarles
Journal:  Kidney Int       Date:  2008-08-27       Impact factor: 10.612

10.  Phosphorylation of Ribosomal Protein S6 Mediates Mammalian Target of Rapamycin Complex 1-Induced Parathyroid Cell Proliferation in Secondary Hyperparathyroidism.

Authors:  Oded Volovelsky; Gili Cohen; Ariel Kenig; Gilad Wasserman; Avigail Dreazen; Oded Meyuhas; Justin Silver; Tally Naveh-Many
Journal:  J Am Soc Nephrol       Date:  2015-08-17       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.